Literature DB >> 19959258

[A proposed guideline for economic evaluation of health technologies].

Julio López Bastida1, Juan Oliva, Fernando Antoñanzas, Anna García-Altés, Ramón Gisbert, Javier Mar, Jaume Puig-Junoy.   

Abstract

Over the last few years, economic evaluation of health technologies has become a major tool used by European health policy decision-makers to create strategies for prioritizing the allocation of health resources and the approval of new technologies. Spain was a pioneer in proposing the standardization of methodology applicable to economic evaluation studies. However, because health policy decision-makers refused to support the initiative, the methodology was never put into practice. In the medium term, evidence of the economic value of new health technologies financed by the national health system will probably be increasingly required. At that time, stakeholders and decision-makers will have to agree upon a clear and concise set of rules on the technical and methodological issues that must be followed by economic evaluations of health technologies. Consequently, we have provided guidelines and recommendations for producing first-rate economic evaluations. The recommendations appear under seventeen headings or sections. In each case, the recommended requirements to be satisfied by an economic evaluation of health technologies are provided and each recommendation is followed by a commentary, providing a justification and comparing and contrasting the proposal with other available alternatives. Copyright (c) 2009 SESPAS. Published by Elsevier Espana. All rights reserved.

Mesh:

Year:  2009        PMID: 19959258     DOI: 10.1016/j.gaceta.2009.07.011

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  50 in total

1.  New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.

Authors:  Fernando Antoñanzas; Pedro Gómez
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010.

Authors:  Angel Sanz-Granda; Alvaro Hidalgo; Juan E del Llano; Joan Rovira
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

3.  Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Authors:  K Kim; A Svedbom; X Luo; S Sutradhar; J A Kanis
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

4.  Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Authors:  C Camps-Herrero; L Paz-Ares; M Codes; R López-López; A Antón-Torres; P Gascón-Vilaplana; V Guillem-Porta; A Carrato; J J Cruz-Hernández; C Caballero-Díaz; A Blasco-Cordellat; J A Moreno-Nogueira; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2014-06-13       Impact factor: 3.405

5.  Stage- and age-adjusted cost-effectiveness analysis of laparoscopic surgery in rectal cancer.

Authors:  Javier Mar; Ane Anton-Ladislao; Oliver Ibarrondo; Arantzazu Arrospide; Santiago Lázaro-Aramburu; Nerea Gonzalez; Marisa Bare; Antonio Escobar; Maximino Redondo; José M Quintana
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

6.  Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.

Authors:  Francisco Jódar-Sánchez; Amaia Malet-Larrea; José J Martín; Leticia García-Mochón; M Puerto López Del Amo; Fernando Martínez-Martínez; Miguel A Gastelurrutia-Garralda; Victoria García-Cárdenas; Daniel Sabater-Hernández; Loreto Sáez-Benito; Shalom I Benrimoj
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

7.  Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.

Authors:  María Del Carmen Vennera; Antonio Valero; Estefany Uría; Carles Forné; César Picado
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

8.  Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.

Authors:  Marina De Salas-Cansado; Enrique Álvarez; José M Olivares; Jose L Carrasco; M Belén Ferro; Javier Rejas
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-21       Impact factor: 4.328

9.  Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain.

Authors:  Fernando de Andrés-Nogales; María Álvarez; María Ángeles de Miquel; Tomás Segura; Alberto Gil; Pere Cardona; Miguel Ángel Casado; Raul G Nogueira; Antoni Dávalos
Journal:  Eur Stroke J       Date:  2017-08-01

10.  Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Authors:  Elena Galve-Calvo; Eva González-Haba; Joana Gostkorzewicz; Irene Martínez; Alejandro Pérez-Mitru
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.